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Abstract
AIM
To evaluate waiting list (WL) registration and liver 
transplantation (LT) rates in patients with hepatitis C 
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virus (HCV)-related cirrhosis since the introduction of 
direct-acting antivirals (DAAs).
METHODS
All adult patients with cirrhosis listed for LT at 
Padua University Hospital between 2006-2017 were 
retrospectively collected using a prospectively-
updated database; patients with HCV-related cirrhosis 
were divided by indication for LT [dec-HCV vs  HCV/ 
hepatocellular carcinoma (HCC)] and into two interval 
times (2006-2013 and 2014-2017) according to the 
introduction of DAAs. For each patient, indications to 
LT, severity of liver dysfunction and the outcome in the 
WL were assessed and compared between the two 
different time periods. For patients receiving DAA-based 
regimens, the achievement of viral eradication and the 
outcome were also evaluated.  
RESULTS
One thousand one hundred and ninty-four [male 
(M)/female (F): 925/269] patients were included. 
Considering the whole cohort, HCV-related cirrhosis 
was the main etiology at the time of WL registration 
(490/1194 patients, 41%). HCV-related cirrhosis 
significantly decreased as indication to WL registration 
after DAA introduction (from 43.3% in 2006-2013 to 
37.2% in 2014-2017, P  = 0.05), especially amongst dec-
HCV (from 24.2% in 2006-2013 to 15.9% in 2014-2017, 
P  = 0.007). Even HCV remained the most common 
indication to LT over time (289/666, 43.4%), there was 
a trend towards a decrease after DAAs introduction (from 
46.3% in 2006-2013 to 39% in 2014-2017, P  = 0.06). 
HCV patients (M/F: 43/11, mean age: 57.7 ± 8 years) 
who achieved viral eradication in the WL had better 
transplant-free survival (log-rank test P  = 0.02) and 
delisting rate (P  = 0.002) than untreated HCV patients. 
CONCLUSION
Introduction of DAAs significantly reduced WL 
registrations for HCV related cirrhosis, especially in the 
setting of decompensated cirrhosis.
Key words: Liver transplantation; Hepatitis C; Cirrhosis; 
Sustained virological response
© The Author(s) 2018. Published by Baishideng 
Publishing Group Inc. All rights reserved.
Core tip: All-oral direct-acting antivirals significantly 
modify the natural history of hepatitis C virus (HCV) 
infection. According to our study, liver transplantation 
for HCV decompensated cirrhosis will decrease in the 
next future. 
Ferrarese A, Germani G, Gambato M, Russo FP, Senzolo M, 
Zanetto A, Shalaby S, Cillo U, Zanus G, Angeli P, Burra P. 
Hepatitis C virus related cirrhosis decreased as indication to 
liver transplantation since the introduction of direct-acting 
antivirals: A single-center study. World J Gastroenterol 2018; 
24(38): 4403-4411  Available from: URL: http://www.wjgnet.
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org/10.3748/wjg.v24.i38.4403
INTRODUCTION
Hepatitis C virus (HCV)-related liver disease has been 
the most common indication for liver transplantation 
(LT) in Western Europe for the last 20 years[1]. In 
Italy, due to the high prevalence of HCV in the general 
population[2,3], HCV-related decompensated cirrhosis 
and hepatocellular carcinoma (HCC) have been the 
main indications for LT to date[4]. The scenario of HCV 
treatment has evolved rapidly since 2011, due to the 
approval of oral direct-acting antiviral agents (DAAs). 
The first oral interferon-free drug available worldwide, 
sofosbuvir, was registered in Italy in 2014[5]. Since 
then, several highly-effective and well-tolerated DAA 
regimens have been approved, with real-life data 
confirming the high sustained virological response 
(SVR) rates seen in the registration trials, even in the 
setting of end-stage liver disease[6-8]. Improvement 
in liver function, as measured by Child-Turcotte-Pugh 
(CTP) and MELD scores, are reported in nearly two 
in three decompensated cirrhotic patients treated 
with DAAs[9,10]. These safe and effective new antiviral 
therapies will probably lead to a reduction of waiting list 
(WL) registrations due to HCV[11,12]. However, the role of 
DAAs in the Italian scenario has not been explored yet.
Therefore, the aims of our study were to evaluate 
the changing rates of waiting list (WL) registrations 
and LT for patients with HCV-related cirrhosis, with or 
without HCC, after introduction of DAAs.
MATERIALS AND METHODS
All patients registered on the WL for LT at Padua 
University Hospital between January 2006 and December 
2017 were assessed. After WL registration, patients’ data 
were collected prospectively in an electronic database. 
Patients with acute liver failure, with indications for LT 
other than cirrhosis, re-LT, or patients younger than 18 
years old were excluded from the study. Patients were 
divided into two main groups according to indication to 
WL registration: patients with HCC and compensated 
liver disease (e.g. MELD < 15; HCC-group), and patients 
with decompensated disease, independently from 
presence of HCC (e.g. MELD ≥ 15 or complications 
of portal hypertension; dec-group). Patients with a 
combined diagnosis of HCV and other cause of liver 
disease (e.g., alcohol, autoimmune liver disease) were 
classified as HCV. Alcohol-related or HBV-related (or 
HBV/HDV) liver disease were diagnosed according 
to current guidelines[13], and they were assessed in 
separate groups. Similarly, all patients with autoimmune, 
cholestatic liver diseases or less common indications to 
LT were grouped together. Patients listed for cryptogenic 
cirrhosis who had a body mass index (BMI) > 30 were 
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classified as metabolic liver disease[14,15], and grouped 
together with patients having a known diagnosis of non-
alcoholic steatohepatitis (NASH). Patients with diagnosis 
of HCC were received WL prioritization according to 
previously published policy[16], updated in 2016[16,17]. 
Patients with HCV-related liver disease were treated from 
2014 with DAAs, according to the recommendations 
of the national regulatory agency[5]. Each patient was 
strictly followed-up during and after treatment with 
DAA; only patients with durable clinical improvements 
after SVR achievement were delisted. Patients were also 
divided into two different time intervals: pre-DAA period 
(2006-2013) and post-DAA period (2014-2017). 
Outcome data were collected at the latest available 
follow-up for each patient. Informed consent was 
obtained, and the study was approved by the local Ethical 
Committee (Comitato Etico per la Sperimentazione 
Clinica della Provincia di Padova, n. AOP/1405).
Statistical analysis
Categorical and continuous variables were calculated 
as frequencies and means ± SD, respectively, and were 
compared using the Fisher’s test or Student’s t-test, as 
appropriate. P values < 0.05 were considered statistically 
significant. Survival analyses were performed using 
Kaplan-Meier curves (log-rank test). Analyses were 
performed using SPSS software version 18 (Chicago, IL, 
United States).
RESULTS
A total of 1469 patients were listed for LT at Padua 
University Hospital from January 2006 to December 
2017. Two hundred seventy-five patients (18.7%) were 
excluded from the study for the following reasons: 
100 (6.8%) patients were younger than 18 years old 
at WL registration, 87 (5.9%) patients had undergone 
previous LT, and 88 (6%) patients did not have cirrhosis 
as indication for LT, leaving 1194 (81.3%) patients for 
the current analysis. 
Considering this cohort, overall WL registration rates 
increased from 94/year in 2006-2013 to 110/year in 
2014-2017, with a concomitant rise in the number of 
LT performed overtime, from 51/year in 2006-2013 to 
69.5/year in 2014-2017 (Figure 1).
Trajectories of WL registrations for HCV-related disease 
before and after DAA introduction
Overall, HCV related liver disease (490/1194, 41%), 
with or without HCC, was the main indication for WL 
registration over time, followed by alcohol and HBV 
(24% and 15.5%, respectively). At WL registration, 
there were no differences between HCV and non-HCV 
patients in terms of age, gender, BMI, however HCV 
patients had higher prevalence of HCC (61.8% vs 42%; 
P = 0.001), and lower MELD score (15 ± 6 vs 16.7 ± 6.8, 
P = 0.01) compared with non-HCV patients (Table 1).  
When WL registration rates were compared in the 
whole cohort between pre-DAA and post-DAA periods, 
HCV significantly decreased as indication to LT (43.3% in 
2006-2013 vs 37.2% in 2014-2017, P = 0.05). Notably, 
there was a significant drop in the WL registration rates 
for dec-HCV (from 24.2% in 2006-2013 to 15.9% in 
2014-2017, P = 0.007), whereas HCV/HCC remained 
a stable indication (from 19% in 2006-2013 to 21% in 
2014-2017, P = 0.4, Figure 2). 
Dec-HCV patients had similar characteristics al 
WL registration between two different interval time 
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Figure 1  Overall trends in waiting list registrations and liver transplantations at Padua University Hospital in the study period. WL: Waiting list; LT: Liver 
transplantation.
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to LT over time (43.4%), followed by alcohol and HBV 
(22.6% and 16%, respectively). At the time of LT, HCV 
patients were older than non-HCV patients (57 ± 7.5 vs 
55 ± 10, P = 0.02), and had lower CTP score (P = 0.03) 
and MELD score (17 ± 8 vs 18 ± 8, P = 0.01) (Table 3). 
Overall, there a was a trend towards a decrease in 
LTs for HCV related disease after DAA introduction (from 
46.3% in 2006-2013 to 39% of overall LT in 2014-2017, 
P = 0.06). When HCV patients were stratified according 
to the main indication to transplantation, LT rates for 
decompensated disease (from 23.4% in 2006-2013 
to 18.3% in 2014-2017, P = 0.1) and for HCC (from 
22.9% in 2006-2013 to 20.8% in 2014-2017, P = 0.5) 
did not significantly change (Figure 3). 
Characteristics of dec-HCV patients at time of LT 
did not differ across the two periods, except for a 
higher prevalence of HCC at the time of transplant in 
periods, whereas HCV/HCC patients in the last period 
were older (57 ± 7 years vs 59 ± 6 years, P = 0.03) 
and had lower CTP score (P = 0.01). The number of 
patients registered in the WL after achievement of SVR 
was higher in the post-DAA period, both amongst dec-
HCV (7.3% in 2006-2013 vs 24.2% in 2014-2017, P 
= 0.004) and HCV/HCC (from 7% in 2006-2013 to 
25.5% in 2014-2017, P = 0.001). Similarly, there was a 
significant increase in treatments while on the WL after 
DAA introduction, both amongst dec-HCV (from 4.9% 
in 2006-2013 to 20% in 2014-2017, P = 0.009) and 
HCV/HCC patients (from 4% in 2006-2013 to 26.5% in 
2014-2017, P = 0.001) (Table 2).
Trajectories of LT for HCV-related disease before and 
after DAA introduction
Overall, HCV related disease remained the first indication 
Table 1  Characteristics at waiting list registration between hepatitis C virus and non- hepatitis C virus patients
HCV n  = 490 (%) Non-HCV n  = 704 (%) P  value
Age (yr) 56 ± 7.8 55 ± 10 ns
Gender (male) 393 (80) 532 (75.5) ns
BMI 25 ± 4 25 ± 4 ns
Blood group ns
   0 206 (42) 311 (44.2)
   A 199 (40.6) 282 (40)
   AB 19 (3.8) 30 (4.3)
   B 66 (13.4) 81 (11.5)
HCC (yes) 303 (61.8) 295 (42) 0.001
Child-Pugh classes 0.04
   A 137 (28) 163 (23)
   B 185 (38) 252 (36)
   C 168 (34) 289 (41)
MELD at WL registration 15 ± 6 16.7 ± 6.8 0.01
HCV: Hepatitis C virus; BMI: Body mass index; HCC: Hepatocellular carcinoma; MELD: Model of End-Stage Liver Disease; WL: Waiting list.
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the post-DAA period (20.8% in 2006-2013 vs 37.3% 
in 2014-2017, P = 0.04). Similarly, no significant 
differences were found on characteristics of HCV/
HCC patients at time of LT between the two periods. 
Prevalence of patients transplanted after achievement 
of SVR was significantly higher in the post-DAA period, 
both amongst dec-HCV (from 8.8% in 2006-2013 to 
29.4% in 2014-2017, P = 0.01) and HCV/HCC (from 
11% in 2006-2013 to 41% in 2014-2017, P = 0.0001) 
(Table 4).
Outcome of HCV patients treated with DAA in the setting 
of LT
Since 2014, 88 out of 164 (53.5%) patients with HCV 
Table 2  Characteristics of hepatitis C virus patients at waiting list registration before and after direct-acting antiviral introduction, 
according to indication to waiting list registration (decompensated liver disease or hepatocellular carcinoma)
dec-HCV HCV/HCC
Pre-DAA n  = 181 (%) Post-DAA n  = 70 (%) P  value Pre-DAA n  = 144 (%) Post-DAA n  = 94 (%) P  value
Gender (male) 139 (77) 53 (75.7) ns 118 (82) 82 (87) ns
Age (yr) 55 ± 8 55 ± 9 ns 57 ± 7 59 ± 6 0.03
BMI 25 ± 3 25 ± 4 ns 24.7 ± 3 25 ± 3.6 ns
Refractory ascites (yes) 74 (40) 32 (45.7) ns - -
Blood group ns ns
   0 86 (47.8) 32 (45.7) 62 (43) 35 (39)
   A 70 (38.4) 25 (35.7) 52 (36) 42 (44)
   AB 4 (2.2) 4 (5.7) 6 (4) 5 (5)
   B 21 (11.5) 9 (12.8) 24 (17) 12 (12)
HCC (yes) 41 (22.5) 24 (34.2) ns - -
Comorbidities ns ns
   None 134 (74.1) 44 (62.8) 104 (72.2) 76 (80)
   HBV 7 (3.8) 2 (2.8) 8 (5.5) 3 (3.2)
   Alcohol 34 (18.6) 19 (27.1) 26 (18) 10 (10.6)
   Metabolic 6 (3.2) 5 (7.3) 6 (4.3) 5 (5.3)
Child-Pugh classes ns 0.01
   A 6 (3.3) 3 (4.2) 64 (44.5) 64 (68)
   B 67 (37) 25 (35.7) 67 (46.5) 26 (27)
   C 108 (59.6) 42 (60) 13 (9) 4 (4)
MELD score 18.7 ± 6 19.3 ± 6 ns 11 ± 3.5 11 ± 3.4 ns
HCV Genotype1 ns ns
   1a 18 (15.1) 14 (23) 11 (10.2) 16 (18.8)
   1b 68 (57.1) 34 (55.7) 67 (62) 39 (45.8)
   2 12 (10) 3 (4.9) 10 (9.3) 4 (4.7)
   3 16 (13.4) 6 (9.8) 15 (13.9) 22 (25.8)
   4 5 (3.3) 4 (6.5) 5 (4.6) 4 (4.7)
SVR achievement
   None 159 (87.8) 39 (55.7) 128 (89) 45 (47.8)
   Before WL registration 13 (7.1) 17 (24.2) 0.004 10 (7) 24 (25.5) 0.001
   IFN based 13 (7.1) 2 (2.8) 10 (7) 6 (6.3)
   During WL registration 9 (4.9) 14 (20) 0.009 6 (4) 25 (26.5) 0.001
1HCV genotype was available in 373 patients at the time of WL registration. HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; DAA: Direct-acting 
antivirals; BMI: Body mass index; HBV: Hepatitis B virus; MELD: Model of End-Stage Liver Disease; SVR: Sustained virological response; WL: Waiting list.
Table 3  Characteristics at the time of liver transplantation between hepatitis C virus and non-hepatitis C virus patients n  (%)
HCV n  = 289 Non-HCV n  = 377 P value
Age (yr) 57 ± 7.5 55 ± 10 0.02
Gender (male) 240 (83) 288 (76) 0.04
Blood group ns
   0 118 (40.8) 167 (44.2)
   A 124 (43) 147 (39)
   AB 12 (4.1) 19 (5)
   B 35 (12.1) 44 (11.8)
Child-Pugh classes
   A 82 (25) 84 (22.2)
   B 99 (36.7) 116 (30.7) 0.03
   C 108 (38.2) 177 (47)
MELD score 17 ± 8 19 ± 8 0.01
Waiting time (mo) 9.6 ± 12 10 ± 14 ns
HCV: Hepatitis C virus; MELD: Model of End-Stage Liver Disease.
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related cirrhosis were treated with DAA in the setting 
of LT (Table 5). Thirty-four (20%) were listed after 
achievement of SVR, whereas 54 (32.9%) were treated 
while on the WL. The SVR rate after first treatment with 
DAA was 88%. Ten patients relapsed after treatment 
with DAA and achieved SVR after a second treatment 
while they were on the WL. Sofosbuvir-based regimens 
were mostly used, whereas ribavirin was used in 43% 
of patients. 
Considering only patients treated while in the WL, 
28 (51%) patients underwent LT, whereas 10 (18%) 
were delisted due to improvement of liver disease, 8 
(14.8%) died, and 2 (3.7%) dropped-out due to HCC 
progression. DAA-treated patients had a higher delisting 
rate due to improvement of liver disease than untreated 
HCV patients over time (18% vs 2.5%, P = 0.002), and 
Table 4  Characteristics of hepatitis C virus patients at liver transplantation before and after direct-acting antiviral introduction, 
according to indication to waiting list registration (decompensated liver disease or hepatocellular carcinoma) n  (%)
dec-HCV HCV/HCC
Pre-DAA n  = 91 Post-DAA n  = 51 P  value Pre-DAA n  = 89 Post-DAA n  = 58 P  value
Gender (male) 74 (81) 40 (78.4) ns 77 (86.5) 49 (84.5) ns
Age (yr) 54.8 ± 8 56 ± 8 ns 57 ± 7 58 ± 7 ns
Refractory ascites (yes) 37 (40.6) 27 (53) ns - -
Blood group ns ns
   0 41 (45) 21 (41.7) 37 (41.5) 19 (32.7)
   A 35 (38) 22 (43.3) 39 (43.8) 28 (54.9)
   AB 3 (3.3) 3 (5.8) 4 (4.5) 2 (3.4)
   B 12 (13) 5 (9.8) 9 (10.2) 9 (15.5)
HCC (yes) 19 (20.8) 19 (37.3) 0.04 - -
Child-Pugh classes ns 0.001
   A 3 (3.2) 1 (1.9) 38 (42.6) 42 (72.4)
   B 27 (29.6) 17 (33.3) 42 (47.2) 12 (20.6)
   C 61 (67.1) 33 (64.7) 9 (10) 4 (6.8)
MELD at LT 24 ± 6.5 23 ± 7.5 ns 11.7 ± 4 11.2 ± 3 ns
SVR at time of LT (yes) 8 (8.8) 15 (29.4) 0.002 10 (11) 24 (41) 0.0001
SVR after IFN-based regimens 7 (7.6) 2 (3.9) 9 (10.1) 1 (1.7)
Waiting time (mo) 8.3 ± 12 10.6 ± 12 ns 9 ± 7.7 10 ± 11 ns
HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; DAA: Direct-acting antivirals; BMI: Body mass index; MELD: Model of End-Stage Liver Disease; 
LT: Liver transplantation; SVR: Sustained virological response.
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Figure 3  Trends in liver transplantation before and after direct-acting antiviral introduction. ALD: Alcoholic liver disease; DAA: Direct-acting antivirals; HBV: 
Hepatitis B virus; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; NASH: Non-alcoholic steatohepatitis.
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a better transplant free survival (log-rank P = 0.02). 
DISCUSSION
In recent decades, HCV-related cirrhosis has been 
considered the most prevalent indication for LT in the 
Western Countries, for both decompensated liver disease 
and HCC. The introduction of DAAs has significantly 
modified the natural history of HCV infection, and viral 
eradication (especially in patients with compensated 
cirrhosis) has been associated with an improvement of 
liver function. We consequently explored dynamics of 
long-term changes in WL registrations and LTs in Our 
Centre. 
Spanning more than a decade, we found that HCV 
remained the main indication for WL registration not 
only before, but also after DAA introduction. This might 
be because the first-generation protease inhibitors were 
approved in Italy since January 2013[18], but their use 
was initially limited by side effects and low rates of SVR 
achievement (less than 50% in cirrhotic patients)[19]. 
Extended approval of DAA therapies was granted in 
Italy in 2014, producing a significant drop in the WL 
registrations for HCV related cirrhosis, moving from 
43.3% in the pre-DAA period to 37.2% in 2014-2017. 
These results are consistent with data recently published 
by another tertiary center in Italy[20], where the 
proportion of dec-HCV patients decreased from 49% 
to 36% in the last years. Two possible explanations 
may be hypothesized; first, a significant change in 
HCV epidemiology in Italy in recent years, as shown by 
several studies[3,21,22], with the highest prevalence of HCV 
in patients over 70 years old (who are not eligible for LT 
anymore); second, the achievement of SVR after DAA 
therapies[23-25], leading to improvement in liver function 
and reduction of portal-hypertensive complications[26]. 
Thus, previously decompensated patients, potentially 
suitable for LT, would therefore not be placed on the WL. 
On the contrary, in the setting of HCV related 
cirrhosis, proportion of WL registration for HCC remained 
stable after DAA introduction (from 19% in 2006-2013 
to 21% in 2014-2017; P = ns). Notably, in the post-DAA 
period, HCC became the first indication to LT amongst 
HCV patients. This trend was confirmed also in patients 
with decompensated disease (e.g. MELD ≥ 15), in 
whom the prevalence of HCC at the time of transplant 
rose from 20.8% in 2006-2013 to 37.3% in 2014-2017. 
Development of HCC in patients previously treated 
with DAA is debated. Several studies[6,27-29] recently 
showed that HCC may still occur or recur in patients with 
SVR achievement after DAA therapy (probably due to 
changes in the immunological microenvironment after 
viral clearance), and these patients would probably still 
need for LT. 
In our experience, nearly 18% of HCV patients were 
delisted after achieving SVR, in a significantly higher 
proportion than in the pre-DAA period. This reinforces 
the concept that SVR achievement could significantly 
improve liver function and increase delisting rate in the 
next future, even if we’ll expect that HCV patients will 
be cured before decompensation, without requiring WL 
registration. Furthermore, our data were consistent with 
those reported by Belli et al[30], who reported a delisting 
rate of 20% (though they only considered HCV-related 
decompensated cirrhosis patients without HCC). 
Our study retrospectively collected all data regarding 
cirrhotic patients from WL registration to final outcome, 
using a prospectively updated electronic database. There 
were no significant changes in WL and LT policies during 
the study period, and the antiviral treatments were 
administered under the supervision of a tertiary center, 
in accordance with the changing criteria recommended 
by the Italian Regulatory Agency. This study has some 
limitations that need to be acknowledged, however. 
It was based on a single-center cohort and covered 
a lengthy period of time. These data, coming from 
a single-center cohort, might not be extended to 
the whole Italian scenario, due to its heterogenous 
epidemiology in terms of etiologies of liver disease. 
However, recently published data from Northern 
Italy seemed to be in accordance with our results[20]. 
Furthermore, criteria for NASH diagnosis significantly 
changed over, so we included patients with cryptogenic 
cirrhosis and a BMI > 30, as other Authors had done[15]. 
Lastly, we were assessing trends of the WL for LT, and 
some misdiagnosed comorbidities may have interfered 
Table 5  Characteristics of hepatitis C virus patients who 
achieved sustained virological response after treatment with 
direct-acting antivirals while in the waiting list n  (%)
SVR after DAA before 
the WL n  = 34 
SVR after DAA in 
the WL n  = 54
Age (yr) 58 ± 8 57.7 ± 8
Gender (male) 25 (73.5) 43 (79.6)
dec-HCV (yes) 15 (44) 44 (44.4)
MELD score before treament - 13 ± 5
HCV genotype
   1a 6 (17.6) 6 (11)
   1b 17 (50) 34 (63)
   2 2 (5.8) 2 (3.7)
   3 7 (20.5) 7 (13)
   4 2 (5.8) 5 (9.3)
Treatment regimens
   Sofosbuvir 4 (11.7) 27 (50)
   Sofosbuvir/Ledipasvir 23 (67.6) 18 (33.3)
   Sofosbuvir/Daclatasvir 3 (8.8) 3 (5.5)
   Sofosbuvir/Simeprevir 1 (2.9) 4 (7.4)
   Other 5 (14.7) 2 (3.7)
Ribavirin use (yes) 1 (2.9) 37 (68.5)
MELD score after treament 12.3 ± 4 13 ± 6
Outcome
   Waiting for LT 16 (47) 6 (11)
   Delisted 1 (2.9) 10 (18.5)
   LT 10 (29.4) 28 (51.8)
   Drop out 5 (14.7) 2 (3.7)
   Dead 2 (5.8) 8 (14.8)
SVR: Sustained virological response; DAA: Direct-acting antivirals; HCV: 
Hepatitis C virus; MELD: Model of End-Stage Liver Disease; LT: Liver 
transplantation.
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with the natural history of several patients. 
In conclusion, our study showed the significant 
changes occurring in the LT scenario. Even if DAA 
therapies have significantly contributed to a decrease 
in the WL registration for dec-HCV, it will take more 
time for HCV to disappear as an indication for liver 
transplantation, especially in the setting of LT for HCC. 
ARTICLE HIGHLIGHTS
Research background
Hepatitis C virus (HCV)-related cirrhosis has been the first indication for liver 
transplantation in Western Countries in the last decades. Introduction of all-oral 
direct-acting antivirals (DAAs) significantly modified the natural history of HCV 
related liver disease. 
Research motivation
Our study aimed at evaluating the change in waiting list registrations and in liver 
transplantation for HCV related cirrhosis after DAAs introduction. 
Research objectives
To evaluate the outcome of patients with HCV related cirrhosis, listed for liver 
transplantation at Padua University Hospital between 2006 and 2017. Patients 
were further divided according to two different time periods (2006-2013 vs 
2014-2017) and according to indication to liver transplantation (decompensated 
disease vs hepatocellular carcinoma).
Research methods
The outcome of patients listed for liver transplantation (LT) for HCV related 
cirrhosis was retrospectively analysed using a prospectively updated database.
Research results
After DAAs introduction, HCV-related cirrhosis significantly decreased 
as indication to waiting list registration, especially among patients with 
decompensated disease. Considering liver transplantation, even HCV remained 
the most common indication to LT over time (289/666, 43.4%), there was a 
trend towards a decrease in the last time period (2013-2017). Furthermore, 
HCV patients who achieved viral eradication had better transplant-free survival 
than untreated HCV patients.
Research conclusions
The study demonstrated that HCV related cirrhosis might be a decreasing 
indication to liver transplantation, especially for decompensated liver 
disease. Viral eradication achieved with DAA-based regimens should reduce 
decompensation rates and need to LT. This study confirmed what already 
known in literature about the beneficial role provided by DAAs in patients with 
HCV related cirrhosis. Viral eradication obtained after DAAs- based regimens 
should reduce decompensation rates amongst patients with HCV related 
cirrhosis. Future studies are needed to confirm the changing scenario regarding 
indications to LT in Western countries.
Research perspectives
Viral eradication obtained after DAA therapy should reduce decompensation 
rates amongst patients with HCV related cirrhosis. To further investigate trends 
in waiting list registrations and liver transplantations for HCV related cirrhosis, 
especially in the setting of hepatocellular carcinoma. Larger, multicentre, 
prospective studies are the best methods for the future research.
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